soul trial oral semaglutide cardiovascular outcomes nejm 2025 results (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Semaglutide and Cardiovascular Outcomes in

Rare : allergic reactions (particularly to methionine or preservatives), injection site inflammation

59 Histology Minimal-deviation melanoma is characterized by an expansile nodule either confined to the papillary dermis (for which the appellation borderline melanoma was applied by Richard Reed) or permeative of the reticular dermis (minimal-deviation melanoma), hence resembling at scanning magnification fully evolved level III or IV vertical growth phase malignant melanoma (Figure 18)

Sasseville et al

These medications are designed to be used as part of a multidisciplinary treatment plan for the disease of obesity